Paper34999727
Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
Loschi M and 7 others. Bone Marrow Transplant, 2022. Cited by 52 papers, by iCite.
Cite this record
ConductScience Library. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Papers, record 34999727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34999727
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematologic Neoplasms | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Myelodysplastic Syndromes | Major topic |
| Humans | |
| Mutation | |
| Ubiquitin-Activating Enzymes |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32320566 | Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32320566 | PubMed |
| 2 | 33619558 | Therapeutic options in VEXAS syndrome: insights from a retrospective series. | Blood | 2021 | https://conductscience.org/library/papers/33619558 | PubMed |
| 3 | 26922775 | Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. | Leuk Res | 2016 | https://conductscience.org/library/papers/26922775 | PubMed |
| 4 | 34427584 | Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. | Blood Adv | 2021 | https://conductscience.org/library/papers/34427584 | PubMed |
| 5 | 24507810 | Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? | Best Pract Res Clin Haematol | 2013 | https://conductscience.org/library/papers/24507810 | PubMed |
| 6 | 28088653 | Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. | Leuk Res | 2017 | https://conductscience.org/library/papers/28088653 | PubMed |
| 7 | 26875020 | Autoimmune diseases and myelodysplastic syndromes. | Am J Hematol | 2016 | https://conductscience.org/library/papers/26875020 | PubMed |
| 8 | 34714914 | Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. | Blood Adv | 2022 | https://conductscience.org/library/papers/34714914 | PubMed |
| 9 | 34651299 | Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. | Br J Haematol | 2022 | https://conductscience.org/library/papers/34651299 | PubMed |
| 10 | 33108101 | Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/33108101 | PubMed |
| 11 | 34632574 | Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. | Br J Dermatol | 2022 | https://conductscience.org/library/papers/34632574 | PubMed |
| 12 | 34046042 | Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. | Front Immunol | 2021 | https://conductscience.org/library/papers/34046042 | PubMed |
| 13 | 34611997 | VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis. | Arthritis Rheumatol | 2022 | https://conductscience.org/library/papers/34611997 | PubMed |
| 14 | 34077653 | Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34077653 | PubMed |
| 15 | 20850913 | [Systemic and autoimmune manifestations in myelodysplastic syndromes]. | Rev Med Interne | 2011 | https://conductscience.org/library/papers/20850913 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42358941 | Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report. | Front Immunol | 2026 | https://conductscience.org/library/papers/42358941 | PubMed |
| 42221689 | Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report. | Clin Hematol Int | 2026 | https://conductscience.org/library/papers/42221689 | PubMed |
| 40977752 | JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases. | Dermatol Res Pract | 2025 | https://conductscience.org/library/papers/40977752 | PubMed |
| 40869252 | VEXAS Syndrome: Genetics, Gender Differences, Clinical Insights, Diagnostic Pitfalls, and Emerging Therapies. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40869252 | PubMed |
| 40846800 | Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40846800 | PubMed |
| 40195449 | Mechanisms of hematopoietic clonal dominance in VEXAS syndrome. | Nat Med | 2025 | https://conductscience.org/library/papers/40195449 | PubMed |
| 39385260 | Rare primary vasculitis: update on multiple complex diseases and the new kids on the block. | Adv Rheumatol | 2024 | https://conductscience.org/library/papers/39385260 | PubMed |
| 39347920 | Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients. | Clin Rheumatol | 2024 | https://conductscience.org/library/papers/39347920 | PubMed |
| 39168911 | Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome. | Ann Hematol | 2024 | https://conductscience.org/library/papers/39168911 | PubMed |
| 39081801 | Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome. | Hemasphere | 2024 | https://conductscience.org/library/papers/39081801 | PubMed |
| 39060513 | Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/39060513 | PubMed |
| 38967099 | Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers. | RMD Open | 2022 | https://conductscience.org/library/papers/38967099 | PubMed |
| 38665946 | Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review. | Front Oncol | 2024 | https://conductscience.org/library/papers/38665946 | PubMed |
| 38627861 | Unveiling the clinical spectrum of relapsing polychondritis: insights into its pathogenesis, novel monogenic causes, and therapeutic strategies. | Adv Rheumatol | 2024 | https://conductscience.org/library/papers/38627861 | PubMed |
| 38410307 | Clinical Manifestations in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: A Narrative Review. | Cureus | 2024 | https://conductscience.org/library/papers/38410307 | PubMed |
| 38330178 | Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT. | Blood Adv | 2024 | https://conductscience.org/library/papers/38330178 | PubMed |
| 38130326 | VEXAS Syndrome-Diagnostic Clues for the Dermatologist and Gaps in Our Current Understanding: A Narrative Review. | JID Innov | 2024 | https://conductscience.org/library/papers/38130326 | PubMed |
| 38091008 | Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome. | Blood Adv | 2023 | https://conductscience.org/library/papers/38091008 | PubMed |
| 37738165 | Intrapatient competition of VEXAS syndrome and CML clones. | Blood Adv | 2023 | https://conductscience.org/library/papers/37738165 | PubMed |
| 37666646 | Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism. | Ann Rheum Dis | 2023 | https://conductscience.org/library/papers/37666646 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| UBA1 | 7317 | PubTator's text mining | https://conductscience.org/library/genes/7317 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34999727
GET https://conductscience.org/api/papers/v1/34999727/cited_by?page=2